Jennifer Patnaik
Concepts (358)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Macular Degeneration | 13 | 2023 | 152 | 3.270 |
Why?
| Visual Acuity | 17 | 2023 | 275 | 2.960 |
Why?
| Cataract | 16 | 2023 | 194 | 2.960 |
Why?
| Geographic Atrophy | 7 | 2023 | 51 | 2.560 |
Why?
| Lenses, Intraocular | 6 | 2022 | 45 | 2.140 |
Why?
| Wet Macular Degeneration | 4 | 2023 | 32 | 2.000 |
Why?
| Diabetic Retinopathy | 10 | 2023 | 156 | 1.900 |
Why?
| Phacoemulsification | 11 | 2023 | 104 | 1.880 |
Why?
| Ophthalmology | 4 | 2023 | 77 | 1.270 |
Why?
| Myopia | 6 | 2023 | 37 | 1.200 |
Why?
| Cataract Extraction | 7 | 2023 | 82 | 1.140 |
Why?
| Retinal Detachment | 6 | 2023 | 55 | 1.130 |
Why?
| Retinopathy of Prematurity | 3 | 2022 | 111 | 1.120 |
Why?
| Keratotomy, Radial | 2 | 2022 | 9 | 1.070 |
Why?
| Keratomileusis, Laser In Situ | 2 | 2022 | 16 | 1.040 |
Why?
| Registries | 5 | 2021 | 2020 | 1.020 |
Why?
| Glaucoma | 6 | 2023 | 214 | 0.940 |
Why?
| Photorefractive Keratectomy | 1 | 2022 | 13 | 0.870 |
Why?
| Capsule Opacification | 2 | 2021 | 27 | 0.840 |
Why?
| Eye Diseases | 2 | 2020 | 78 | 0.840 |
Why?
| Presbyopia | 1 | 2022 | 11 | 0.830 |
Why?
| Posterior Capsulotomy | 1 | 2021 | 8 | 0.820 |
Why?
| Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.820 |
Why?
| Lasers, Solid-State | 1 | 2021 | 24 | 0.800 |
Why?
| National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.790 |
Why?
| Automobile Driving | 2 | 2022 | 129 | 0.770 |
Why?
| Laser Therapy | 1 | 2021 | 105 | 0.740 |
Why?
| Retinal Neovascularization | 1 | 2019 | 21 | 0.730 |
Why?
| Retrospective Studies | 39 | 2023 | 13433 | 0.720 |
Why?
| Glaucoma, Open-Angle | 4 | 2023 | 98 | 0.720 |
Why?
| Refraction, Ocular | 5 | 2022 | 31 | 0.680 |
Why?
| Estrogen Replacement Therapy | 1 | 2019 | 118 | 0.670 |
Why?
| Lens, Crystalline | 1 | 2020 | 126 | 0.660 |
Why?
| Humans | 91 | 2023 | 122796 | 0.640 |
Why?
| Strabismus | 3 | 2023 | 27 | 0.630 |
Why?
| Intraoperative Complications | 5 | 2022 | 132 | 0.630 |
Why?
| Vitrectomy | 5 | 2021 | 58 | 0.630 |
Why?
| Metformin | 1 | 2021 | 303 | 0.620 |
Why?
| Internal Medicine | 1 | 2019 | 226 | 0.600 |
Why?
| Uveitis | 3 | 2022 | 116 | 0.600 |
Why?
| West Nile Fever | 3 | 2011 | 52 | 0.600 |
Why?
| Retinal Drusen | 3 | 2021 | 25 | 0.590 |
Why?
| Colorado | 19 | 2023 | 4325 | 0.570 |
Why?
| Trabeculectomy | 4 | 2022 | 71 | 0.560 |
Why?
| Follow-Up Studies | 11 | 2021 | 4768 | 0.560 |
Why?
| Aged | 31 | 2023 | 20495 | 0.560 |
Why?
| Intraocular Pressure | 8 | 2023 | 286 | 0.550 |
Why?
| Emergency Medicine | 1 | 2019 | 260 | 0.550 |
Why?
| Self Report | 2 | 2022 | 730 | 0.540 |
Why?
| Breast Neoplasms | 3 | 2011 | 1994 | 0.520 |
Why?
| Family Practice | 1 | 2019 | 485 | 0.510 |
Why?
| Surveys and Questionnaires | 8 | 2022 | 4882 | 0.510 |
Why?
| Postoperative Complications | 4 | 2022 | 2301 | 0.490 |
Why?
| Aged, 80 and over | 16 | 2021 | 6845 | 0.490 |
Why?
| Female | 48 | 2023 | 63629 | 0.490 |
Why?
| Lens Implantation, Intraocular | 5 | 2022 | 60 | 0.490 |
Why?
| Commerce | 2 | 2013 | 58 | 0.470 |
Why?
| Internet | 4 | 2023 | 686 | 0.450 |
Why?
| Vitreous Body | 4 | 2022 | 104 | 0.450 |
Why?
| Fluocinolone Acetonide | 2 | 2023 | 16 | 0.440 |
Why?
| Smoking Prevention | 1 | 2013 | 150 | 0.430 |
Why?
| Tobacco Products | 1 | 2013 | 74 | 0.430 |
Why?
| Macula Lutea | 2 | 2023 | 15 | 0.420 |
Why?
| Male | 42 | 2023 | 59639 | 0.420 |
Why?
| Retinal Diseases | 2 | 2023 | 81 | 0.400 |
Why?
| Lasers, Excimer | 2 | 2022 | 21 | 0.400 |
Why?
| Disease Notification | 2 | 2011 | 16 | 0.390 |
Why?
| Lens Capsule, Crystalline | 2 | 2021 | 10 | 0.390 |
Why?
| Angiogenesis Inhibitors | 2 | 2023 | 223 | 0.370 |
Why?
| Complement Factor B | 2 | 2022 | 102 | 0.360 |
Why?
| Comorbidity | 2 | 2011 | 1600 | 0.350 |
Why?
| Eye Injuries | 2 | 2021 | 46 | 0.350 |
Why?
| Diabetes Mellitus, Type 2 | 4 | 2023 | 2221 | 0.350 |
Why?
| Complement System Proteins | 3 | 2022 | 296 | 0.340 |
Why?
| Complement Activation | 3 | 2022 | 349 | 0.340 |
Why?
| Diabetes Mellitus | 4 | 2023 | 985 | 0.330 |
Why?
| Cross-Sectional Studies | 7 | 2022 | 4734 | 0.320 |
Why?
| Bangladesh | 3 | 2022 | 40 | 0.310 |
Why?
| Hepatitis A | 2 | 2011 | 28 | 0.310 |
Why?
| West Nile virus | 1 | 2007 | 40 | 0.310 |
Why?
| United States | 14 | 2023 | 13272 | 0.300 |
Why?
| Health Promotion | 1 | 2013 | 707 | 0.290 |
Why?
| Restaurants | 1 | 2006 | 17 | 0.290 |
Why?
| Vision Disorders | 3 | 2022 | 134 | 0.290 |
Why?
| Local Government | 1 | 2006 | 33 | 0.290 |
Why?
| Middle Aged | 20 | 2021 | 28563 | 0.280 |
Why?
| Chronic Disease | 2 | 2011 | 1645 | 0.280 |
Why?
| Risk Factors | 10 | 2023 | 9381 | 0.270 |
Why?
| Public Health Administration | 1 | 2006 | 81 | 0.270 |
Why?
| Chemokine CCL5 | 2 | 2023 | 50 | 0.270 |
Why?
| Gestational Age | 3 | 2022 | 787 | 0.250 |
Why?
| Birth Weight | 3 | 2022 | 473 | 0.250 |
Why?
| Cornea | 2 | 2022 | 120 | 0.250 |
Why?
| Aberrometry | 2 | 2021 | 9 | 0.250 |
Why?
| Prevalence | 5 | 2022 | 2442 | 0.240 |
Why?
| Optics and Photonics | 2 | 2021 | 47 | 0.240 |
Why?
| Refractive Errors | 1 | 2023 | 13 | 0.240 |
Why?
| Time Factors | 5 | 2021 | 6682 | 0.230 |
Why?
| Macular Edema | 1 | 2023 | 37 | 0.230 |
Why?
| Insulins | 1 | 2023 | 35 | 0.230 |
Why?
| Homosexuality, Male | 2 | 2020 | 176 | 0.230 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2023 | 537 | 0.220 |
Why?
| Vision, Low | 1 | 2022 | 13 | 0.220 |
Why?
| Eye Burns | 1 | 2022 | 12 | 0.220 |
Why?
| Eyelid Diseases | 1 | 2022 | 14 | 0.220 |
Why?
| Cohort Studies | 6 | 2022 | 5294 | 0.220 |
Why?
| Outpatient Clinics, Hospital | 1 | 2023 | 84 | 0.220 |
Why?
| Compartment Syndromes | 1 | 2022 | 41 | 0.220 |
Why?
| Eyeglasses | 1 | 2022 | 4 | 0.210 |
Why?
| Corneal Ulcer | 1 | 2022 | 14 | 0.210 |
Why?
| Incidence | 5 | 2022 | 2527 | 0.210 |
Why?
| Scleritis | 1 | 2022 | 18 | 0.210 |
Why?
| Retinal Perforations | 1 | 2022 | 14 | 0.210 |
Why?
| Prospective Studies | 4 | 2023 | 6704 | 0.210 |
Why?
| Clothing | 1 | 2022 | 25 | 0.210 |
Why?
| Odds Ratio | 4 | 2019 | 1043 | 0.210 |
Why?
| Ocular Hypertension | 1 | 2022 | 60 | 0.210 |
Why?
| Fluorescein Angiography | 4 | 2023 | 103 | 0.200 |
Why?
| Glucocorticoids | 2 | 2023 | 554 | 0.200 |
Why?
| Infant | 8 | 2022 | 8523 | 0.200 |
Why?
| Weapons | 1 | 2021 | 10 | 0.200 |
Why?
| Refractive Surgical Procedures | 1 | 2021 | 5 | 0.200 |
Why?
| Civil Disorders | 1 | 2021 | 8 | 0.200 |
Why?
| Perception | 2 | 2021 | 324 | 0.200 |
Why?
| Political Activism | 1 | 2021 | 11 | 0.200 |
Why?
| Glycation End Products, Advanced | 1 | 2021 | 70 | 0.200 |
Why?
| Corneal Transplantation | 1 | 2020 | 10 | 0.200 |
Why?
| Eye Banks | 1 | 2020 | 7 | 0.190 |
Why?
| Sickness Impact Profile | 1 | 2020 | 53 | 0.190 |
Why?
| Neonatal Screening | 1 | 2022 | 185 | 0.190 |
Why?
| Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.190 |
Why?
| Glaucoma Drainage Implants | 1 | 2021 | 49 | 0.190 |
Why?
| Health Status Disparities | 1 | 2023 | 217 | 0.190 |
Why?
| Quality of Life | 5 | 2023 | 2457 | 0.190 |
Why?
| Accidents, Traffic | 1 | 2022 | 179 | 0.190 |
Why?
| Neurodegenerative Diseases | 1 | 2022 | 98 | 0.190 |
Why?
| SEER Program | 2 | 2011 | 206 | 0.190 |
Why?
| Language | 1 | 2023 | 271 | 0.190 |
Why?
| Oculomotor Muscles | 1 | 2020 | 40 | 0.190 |
Why?
| Infant, Newborn | 5 | 2022 | 5430 | 0.180 |
Why?
| Retinal Hemorrhage | 1 | 2019 | 20 | 0.180 |
Why?
| Scleral Buckling | 1 | 2019 | 19 | 0.180 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2019 | 12 | 0.180 |
Why?
| Hepatitis C | 1 | 2022 | 226 | 0.180 |
Why?
| Ophthalmologic Surgical Procedures | 1 | 2020 | 58 | 0.180 |
Why?
| Protective Factors | 1 | 2019 | 96 | 0.180 |
Why?
| Legislation, Drug | 1 | 2020 | 80 | 0.180 |
Why?
| MAP Kinase Kinase 1 | 1 | 2019 | 67 | 0.180 |
Why?
| Head Injuries, Closed | 1 | 2019 | 55 | 0.180 |
Why?
| Refugees | 1 | 2020 | 58 | 0.170 |
Why?
| Complement Membrane Attack Complex | 1 | 2019 | 34 | 0.170 |
Why?
| Specialization | 1 | 2020 | 134 | 0.170 |
Why?
| Complement C3a | 1 | 2019 | 33 | 0.170 |
Why?
| Risk Assessment | 3 | 2019 | 3213 | 0.170 |
Why?
| Cardiovascular Diseases | 1 | 2011 | 1859 | 0.170 |
Why?
| Uveitis, Posterior | 1 | 2019 | 12 | 0.170 |
Why?
| Accreditation | 1 | 2019 | 96 | 0.170 |
Why?
| Choroidal Neovascularization | 1 | 2019 | 45 | 0.170 |
Why?
| Postoperative Period | 4 | 2020 | 317 | 0.170 |
Why?
| Infant, Premature | 1 | 2022 | 507 | 0.170 |
Why?
| Patient Care | 1 | 2019 | 117 | 0.160 |
Why?
| Treatment Outcome | 6 | 2022 | 9692 | 0.160 |
Why?
| Case-Control Studies | 3 | 2022 | 3296 | 0.160 |
Why?
| Medical Marijuana | 1 | 2020 | 103 | 0.160 |
Why?
| Glaucoma, Angle-Closure | 1 | 2018 | 16 | 0.160 |
Why?
| Health Services Needs and Demand | 1 | 2020 | 265 | 0.160 |
Why?
| Trabecular Meshwork | 1 | 2018 | 77 | 0.150 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 204 | 0.150 |
Why?
| Healthcare Disparities | 1 | 2023 | 494 | 0.150 |
Why?
| Marijuana Use | 1 | 2020 | 158 | 0.150 |
Why?
| Marijuana Smoking | 1 | 2020 | 222 | 0.150 |
Why?
| Burnout, Professional | 1 | 2022 | 333 | 0.150 |
Why?
| Sexually Transmitted Diseases | 3 | 2004 | 218 | 0.140 |
Why?
| Recovery of Function | 1 | 2019 | 610 | 0.140 |
Why?
| Logistic Models | 2 | 2019 | 1995 | 0.130 |
Why?
| Inflammation | 3 | 2023 | 2598 | 0.130 |
Why?
| Disease Progression | 1 | 2022 | 2546 | 0.130 |
Why?
| Population Surveillance | 2 | 2011 | 439 | 0.130 |
Why?
| Disease Management | 1 | 2019 | 591 | 0.130 |
Why?
| Child | 7 | 2023 | 19561 | 0.130 |
Why?
| Tomography, Optical Coherence | 3 | 2022 | 134 | 0.130 |
Why?
| Education, Medical, Graduate | 1 | 2019 | 432 | 0.130 |
Why?
| Disease Outbreaks | 2 | 2008 | 333 | 0.120 |
Why?
| Biomarkers | 5 | 2023 | 3662 | 0.120 |
Why?
| Hypoglycemic Agents | 1 | 2021 | 1055 | 0.120 |
Why?
| Physicians | 1 | 2022 | 824 | 0.120 |
Why?
| Condoms | 2 | 2004 | 123 | 0.120 |
Why?
| Research Design | 1 | 2019 | 1002 | 0.110 |
Why?
| Melanoma | 1 | 2019 | 709 | 0.110 |
Why?
| Sexual Behavior | 4 | 2004 | 470 | 0.110 |
Why?
| Clinical Competence | 1 | 2019 | 973 | 0.110 |
Why?
| Telemedicine | 1 | 2021 | 691 | 0.110 |
Why?
| Tertiary Healthcare | 2 | 2022 | 29 | 0.100 |
Why?
| Skin Neoplasms | 1 | 2019 | 841 | 0.100 |
Why?
| Adult | 14 | 2020 | 32385 | 0.100 |
Why?
| Diagnostic Errors | 1 | 2011 | 171 | 0.090 |
Why?
| Shellfish Poisoning | 1 | 2009 | 1 | 0.090 |
Why?
| Vibrio Infections | 1 | 2009 | 2 | 0.090 |
Why?
| Shellfish | 1 | 2009 | 7 | 0.090 |
Why?
| Food Industry | 1 | 2009 | 14 | 0.090 |
Why?
| Food Microbiology | 1 | 2009 | 59 | 0.090 |
Why?
| Primary Prevention | 1 | 2011 | 212 | 0.090 |
Why?
| Cause of Death | 1 | 2011 | 389 | 0.090 |
Why?
| Internship and Residency | 1 | 2019 | 1065 | 0.090 |
Why?
| Mortality | 1 | 2011 | 317 | 0.090 |
Why?
| Adolescent | 6 | 2020 | 18948 | 0.080 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 884 | 0.080 |
Why?
| Cryptosporidiosis | 1 | 2008 | 11 | 0.080 |
Why?
| Academic Medical Centers | 2 | 2022 | 427 | 0.080 |
Why?
| Antineoplastic Agents | 1 | 2019 | 1990 | 0.080 |
Why?
| Anti-Inflammatory Agents | 2 | 2022 | 469 | 0.080 |
Why?
| Proportional Hazards Models | 1 | 2011 | 1184 | 0.080 |
Why?
| Maternal-Child Health Centers | 1 | 2007 | 9 | 0.080 |
Why?
| Disease Reservoirs | 1 | 2007 | 24 | 0.080 |
Why?
| Culicidae | 1 | 2007 | 29 | 0.080 |
Why?
| Sentinel Surveillance | 1 | 2007 | 39 | 0.080 |
Why?
| Health Services Administration | 1 | 2007 | 9 | 0.080 |
Why?
| Gastroenteritis | 1 | 2008 | 65 | 0.080 |
Why?
| Horses | 1 | 2007 | 109 | 0.080 |
Why?
| Telephone | 1 | 2008 | 160 | 0.080 |
Why?
| Chickens | 1 | 2007 | 188 | 0.080 |
Why?
| Relief Work | 1 | 2007 | 23 | 0.080 |
Why?
| Birds | 1 | 2007 | 93 | 0.070 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 839 | 0.070 |
Why?
| Geography | 1 | 2007 | 199 | 0.070 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2023 | 3388 | 0.070 |
Why?
| Predictive Value of Tests | 1 | 2011 | 1947 | 0.070 |
Why?
| Health Care Surveys | 1 | 2008 | 564 | 0.070 |
Why?
| Disasters | 1 | 2007 | 90 | 0.070 |
Why?
| Databases, Factual | 1 | 2011 | 1287 | 0.070 |
Why?
| Medicare | 1 | 2011 | 767 | 0.070 |
Why?
| Immunoglobulins | 1 | 2006 | 166 | 0.070 |
Why?
| Environment | 1 | 2007 | 357 | 0.070 |
Why?
| Smoking | 1 | 2013 | 1556 | 0.070 |
Why?
| Immunization Programs | 1 | 2007 | 210 | 0.070 |
Why?
| Ganglionic Stimulants | 1 | 2005 | 10 | 0.070 |
Why?
| Needs Assessment | 1 | 2007 | 345 | 0.060 |
Why?
| Patient Discharge | 1 | 2011 | 842 | 0.060 |
Why?
| Vision Tests | 1 | 2023 | 15 | 0.060 |
Why?
| Young Adult | 4 | 2020 | 11094 | 0.060 |
Why?
| Hospitals, County | 1 | 2023 | 11 | 0.060 |
Why?
| Attitude to Health | 1 | 2007 | 417 | 0.060 |
Why?
| Electronic Health Records | 1 | 2011 | 842 | 0.060 |
Why?
| Child, Preschool | 4 | 2020 | 9755 | 0.060 |
Why?
| Health Surveys | 2 | 2021 | 468 | 0.060 |
Why?
| Laser Coagulation | 1 | 2023 | 58 | 0.060 |
Why?
| Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| Orbit | 1 | 2022 | 50 | 0.050 |
Why?
| Tobacco Use Disorder | 1 | 2005 | 232 | 0.050 |
Why?
| Interleukin-4 | 1 | 2023 | 230 | 0.050 |
Why?
| Aqueous Humor | 1 | 2022 | 31 | 0.050 |
Why?
| Communication Barriers | 1 | 2023 | 92 | 0.050 |
Why?
| Nicotine | 1 | 2005 | 276 | 0.050 |
Why?
| Phenotype | 2 | 2022 | 3070 | 0.050 |
Why?
| Drug Implants | 1 | 2022 | 71 | 0.050 |
Why?
| Gonorrhea | 1 | 2003 | 72 | 0.050 |
Why?
| Cluster Analysis | 1 | 2023 | 493 | 0.050 |
Why?
| Alanine Transaminase | 1 | 2022 | 152 | 0.050 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 1265 | 0.050 |
Why?
| Reference Standards | 1 | 2022 | 177 | 0.050 |
Why?
| Albumins | 1 | 2022 | 104 | 0.050 |
Why?
| Safety-net Providers | 1 | 2023 | 106 | 0.050 |
Why?
| Capsulorhexis | 1 | 2021 | 8 | 0.050 |
Why?
| Choroid | 1 | 2021 | 47 | 0.050 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 92 | 0.050 |
Why?
| Fibrinogen | 1 | 2022 | 162 | 0.050 |
Why?
| Morbidity | 1 | 2022 | 309 | 0.050 |
Why?
| Dissent and Disputes | 1 | 2021 | 17 | 0.050 |
Why?
| Smoking Cessation | 1 | 2005 | 363 | 0.050 |
Why?
| Intraoperative Period | 1 | 2020 | 56 | 0.050 |
Why?
| Crowding | 1 | 2021 | 37 | 0.050 |
Why?
| Biometry | 1 | 2021 | 65 | 0.050 |
Why?
| Hepacivirus | 1 | 2022 | 234 | 0.050 |
Why?
| Myotomy | 1 | 2020 | 8 | 0.050 |
Why?
| Vision, Binocular | 1 | 2020 | 15 | 0.050 |
Why?
| Intravitreal Injections | 1 | 2020 | 47 | 0.050 |
Why?
| Myanmar | 1 | 2020 | 6 | 0.050 |
Why?
| Risk-Taking | 1 | 2003 | 334 | 0.050 |
Why?
| Rupture | 1 | 2020 | 107 | 0.050 |
Why?
| Eye Movements | 1 | 2020 | 58 | 0.050 |
Why?
| Immunologic Factors | 1 | 2022 | 228 | 0.050 |
Why?
| Health Education | 1 | 2003 | 332 | 0.040 |
Why?
| Chromatography, Liquid | 1 | 2021 | 356 | 0.040 |
Why?
| C-Reactive Protein | 1 | 2021 | 363 | 0.040 |
Why?
| Canada | 1 | 2020 | 355 | 0.040 |
Why?
| HIV | 1 | 2020 | 219 | 0.040 |
Why?
| Adrenal Cortex Hormones | 1 | 2023 | 515 | 0.040 |
Why?
| Circadian Rhythm | 1 | 2023 | 414 | 0.040 |
Why?
| Remission, Spontaneous | 1 | 2019 | 37 | 0.040 |
Why?
| Pyrimidinones | 1 | 2019 | 88 | 0.040 |
Why?
| Microscopy, Acoustic | 1 | 2018 | 8 | 0.040 |
Why?
| Ambulatory Care | 1 | 2023 | 497 | 0.040 |
Why?
| Attitude | 1 | 2021 | 236 | 0.040 |
Why?
| Ophthalmoscopy | 1 | 2018 | 30 | 0.040 |
Why?
| Tandem Mass Spectrometry | 1 | 2021 | 423 | 0.040 |
Why?
| Preoperative Period | 1 | 2019 | 112 | 0.040 |
Why?
| Axial Length, Eye | 1 | 2018 | 9 | 0.040 |
Why?
| Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| Corneal Pachymetry | 1 | 2018 | 16 | 0.040 |
Why?
| Pseudophakia | 1 | 2018 | 11 | 0.040 |
Why?
| Tonometry, Ocular | 1 | 2018 | 92 | 0.040 |
Why?
| Prosthesis Design | 1 | 2020 | 293 | 0.040 |
Why?
| Disease-Free Survival | 1 | 2019 | 661 | 0.040 |
Why?
| Referral and Consultation | 1 | 2022 | 669 | 0.040 |
Why?
| Cost-Benefit Analysis | 1 | 2020 | 573 | 0.040 |
Why?
| Stents | 1 | 2021 | 491 | 0.040 |
Why?
| Ambulatory Care Facilities | 3 | 2004 | 244 | 0.040 |
Why?
| Physical Examination | 1 | 2019 | 253 | 0.040 |
Why?
| Mental Health | 1 | 2022 | 571 | 0.040 |
Why?
| Sex Characteristics | 1 | 2022 | 690 | 0.040 |
Why?
| Sleep | 1 | 2023 | 722 | 0.040 |
Why?
| Equipment Design | 1 | 2018 | 533 | 0.040 |
Why?
| Reproducibility of Results | 1 | 2023 | 2977 | 0.030 |
Why?
| Anxiety | 1 | 2022 | 888 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2019 | 1531 | 0.030 |
Why?
| Program Evaluation | 2 | 2011 | 880 | 0.030 |
Why?
| Proteomics | 1 | 2020 | 890 | 0.030 |
Why?
| Child Abuse | 1 | 2019 | 473 | 0.030 |
Why?
| Proteins | 1 | 2020 | 953 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2022 | 1814 | 0.030 |
Why?
| Depression | 1 | 2022 | 1190 | 0.030 |
Why?
| Protein Kinase Inhibitors | 1 | 2019 | 833 | 0.030 |
Why?
| Pandemics | 1 | 2021 | 1401 | 0.030 |
Why?
| Blood Glucose | 1 | 2021 | 1957 | 0.030 |
Why?
| Animals | 3 | 2009 | 34133 | 0.030 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1402 | 0.030 |
Why?
| Prognosis | 1 | 2019 | 3563 | 0.030 |
Why?
| Legionellosis | 1 | 2011 | 2 | 0.020 |
Why?
| Haemophilus Infections | 1 | 2011 | 32 | 0.020 |
Why?
| Whooping Cough | 1 | 2011 | 50 | 0.020 |
Why?
| Medical Audit | 1 | 2011 | 78 | 0.020 |
Why?
| Hospitals, Urban | 1 | 2011 | 140 | 0.020 |
Why?
| International Classification of Diseases | 1 | 2011 | 128 | 0.020 |
Why?
| Cryptosporidium | 1 | 2008 | 12 | 0.020 |
Why?
| Residence Characteristics | 1 | 2011 | 313 | 0.020 |
Why?
| Caliciviridae Infections | 1 | 2008 | 20 | 0.020 |
Why?
| Norovirus | 1 | 2008 | 25 | 0.020 |
Why?
| Aid to Families with Dependent Children | 1 | 2007 | 4 | 0.020 |
Why?
| Faculty | 1 | 2008 | 133 | 0.020 |
Why?
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2007 | 89 | 0.020 |
Why?
| Family Characteristics | 1 | 2008 | 164 | 0.020 |
Why?
| Medically Uninsured | 1 | 2007 | 133 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2011 | 1855 | 0.020 |
Why?
| Maryland | 1 | 2005 | 39 | 0.020 |
Why?
| Pharmaceutical Preparations | 1 | 2007 | 168 | 0.020 |
Why?
| Guideline Adherence | 1 | 2009 | 560 | 0.020 |
Why?
| Administration, Topical | 1 | 2005 | 154 | 0.020 |
Why?
| Urban Health Services | 1 | 2004 | 66 | 0.020 |
Why?
| Acute Disease | 1 | 2007 | 984 | 0.020 |
Why?
| Patient Satisfaction | 1 | 2008 | 632 | 0.020 |
Why?
| Office Visits | 1 | 2003 | 94 | 0.010 |
Why?
| Syphilis | 1 | 2003 | 37 | 0.010 |
Why?
| Administration, Oral | 1 | 2005 | 786 | 0.010 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2003 | 261 | 0.010 |
Why?
| Mothers | 1 | 2007 | 728 | 0.010 |
Why?
| Urban Population | 1 | 2004 | 425 | 0.010 |
Why?
| Risk | 1 | 2004 | 890 | 0.010 |
Why?
| HIV Infections | 1 | 2003 | 2532 | 0.010 |
Why?
|
|
Patnaik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|